Core Scientific Inc vs Tempus AI — how do they compare? Core Scientific Inc trades at $15.61 (market cap $4.94B), while Tempus AI trades at $70.03 (market cap $12.58B). The key difference: Tempus AI is far larger — about 2.5× Core Scientific Inc's market cap, and Tempus AI is trading nearer its 52-week high, Core Scientific Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Tempus AI for 22 Days on average.
| CORZ | TEM | |
|---|---|---|
Market Cap | $4.94B | $12.58B |
Volume | 15,630,800 | 7,444,569 |
Sector | Technology | Broad Market / Factor |
52-Week High | $29.16 | $99.28 |
52-Week Low | $13.57 | $41.55 |
Typical Hold Time | 20 Days | 22 Days |
Enterprise Value | $7.46B | $13.21B |
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $15.94, down 4.44% today amid bearish technical signals. The stock shows weak fundamentals with a -324.9% net income margin and negative earnings misses in recent quarters. However, analyst sentiment remains overwhelmingly positive with 86% buy ratings and a $32.46 consensus price target. Recent executive appointments and AI data center expansion plans provide growth catalysts despite current profitability challenges.
The outlook balances strong analyst conviction against fundamental weakness. While the AI infrastructure pivot offers long-term potential, investors face significant execution risks and negative cash flow. The stock trades near support levels with technical indicators suggesting caution, requiring careful monitoring of revenue growth and margin improvement for sustained recovery.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →